Pepe Alcami

List of Publications by Year
in descending order

209 papers	8,178 citations	36299 51 h-index	66906 78 g-index
230 all docs	230 docs citations	230 times ranked	11498 citing authors

#	Article	IF	Citations
1	Membrane raft microdomains mediate lateral assemblies required for HIVâ€1 infection. EMBO Reports, 2000, 1, 190-196.	4.5	335
2	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	13.7	316
3	Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature Reviews Microbiology, 2009, 7, 798-812.	28.6	235
4	HIV enhancer activity perpetuated by NF-ÎºB induction on infection of monocytes. Nature, 1991, 350, 709-712.	27.8	209
5	Hydrogen peroxide increases extracellular matrix mRNA through TGF-Î² in human mesangial cells. Kidney International, 2001, 59, 87-95.	5.2	196
6	TRAF Family Proteins Link PKR with NF-ÎºB Activation. Molecular and Cellular Biology, 2004, 24, 4502-4512.	2.3	147
7	Therapeutic Immunization with Dendritic Cells Loaded with Heatâ€Inactivated Autologous HIVâ€1 in Patients with Chronic HIVâ€1 Infection. Journal of Infectious Diseases, 2005, 191, 1680-1685.	4.0	147
8	Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. Journal of Virology, 1994, 68, 5730-5737.	3.4	146
9	Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2718-2721.	2.2	135
10	Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV,the, 2021, 8, e294-e305.	4.7	129
11	Activation of NF-ÎºB by the dsRNA-dependent protein kinase, PKR involves the IÎºB kinase complex. Oncogene, 2000, 19, 1369-1378.	5.9	125
12	Multivalent Mannoâ€Glyconanoparticles Inhibit DCâ€SIGNâ€Mediated HIVâ€1 Transâ€Infection of Human T Cells. ChemBioChem, 2009, 10, 1806-1809.	2.6	117
13	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications, 2019, 10, 2355.	12.8	116
14	Imperatorin Inhibits HIV-1 Replication through an Sp1-dependent Pathway. Journal of Biological Chemistry, 2004, 279, 37349-37359.	3.4	115
15	Plasma Stromal Cellâ€“Derived Factor (SDF)â€1 Levels, SDF1â€3â€²A Genotype, and Expression of CXCR4 on T Lymphocytes: Their Impact on Resistance to Human Immunodeficiency Virus Type 1 Infection and Its Progression. Journal of Infectious Diseases, 2002, 186, 922-931.	4.0	110
16	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. PLoS ONE, 2009, 4, e4505.	2.5	109
17	Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7861-7865.	7.1	108
18	Genomic organization and promoter characterization of human CXCR4 gene1. FEBS Letters, 1998, 426, 271-278.	2.8	107

#	Article	IF	Citations
19	Beyond plasticity: the dynamic impact of electrical synapses on neural circuits. Nature Reviews Neuroscience, 2019, 20, 253-271.	10.2	107
20	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 473-478.	4.0	105
21	Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). Journal of Biological Chemistry, 2011, 286, 33409-33421.	3.4	101
22	The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection.. Journal of Clinical Investigation, 1997, 100, 497-502.	8.2	101
23	A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation, 2021, 131, .	8.2	100
24	Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis and Rheumatism, 2001, 44, 1382-1386.	6.7	97
25	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	30.7	96
26	The Hepatitis B Virus X Protein Induces HIV-1 Replication and Transcription in Synergy with T-cell Activation Signals. Journal of Biological Chemistry, 2001, 276, 35435-35443.	3.4	95
27	Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clinical and Experimental Immunology, 2001, 123, 36-41.	2.6	78
28	NF-kappa B-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7826-7830.	7.1	74
29	New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection. Journal of Biological Chemistry, 2011, 286, 4978-4990.	3.4	73
30	Somatostatin-positive interneurons in the dentate gyrus of mice provide local- and long-range septal synaptic inhibition. ELife, 2017, 6, .	6.0	73
31	Functional Characterization of SDF-1 Proximal Promoter. Journal of Molecular Biology, 2005, 348, 43-62.	4.2	72
32	Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. European Journal of Immunology, 1998, 28, 3192-3204.	2.9	71
33	Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients With Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 823-830.	2.1	71
34	A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. Journal of Medical Virology, 2007, 79, 127-137.	5.0	70
35	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine, 2011, 29, 8309-8316.	3.8	70
36	Anti-HIV activity of medicinal plant extracts. Journal of Ethnopharmacology, 2001, 77, 113-116.	4.1	69

#	Article	IF	Citations
37	4-Phenylcoumarins as HIV transcription inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4447-4450.	2.2	69
38	Rate and predictors of progression in elite and viremic HIV-1 controllers. Aids, 2016, 30, 1209-1220.	2.2	69
39	3-Phenylcoumarins as Inhibitors of HIV-1 Replication. Molecules, 2012, 17, 9245-9257.	3.8	67
40	Modifications in the human Tâ€...cell proteome induced by intracellular HIV-1 Tat protein expression. Proteomics, 2006, 6, S63-S73.	2.2	66
41	Constitutive expression of human immunodeficiency virus (HIV) nef protein in human astrocytes does not influence basal or induced HIV long terminal repeat activity. Journal of Virology, 1990, 64, 3059-3062.	3.4	66
42	The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-Î²B activation. Oncogene, 2001, 20, 385-394.	5.9	64
43	IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle. Cell Reports, 2016, 14, 2100-2107.	6.4	64
44	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. PLoS ONE, 2012, 7, e36438.	2.5	63
45	G Protein-Dependent CCR5 Signaling Is Not Required for Efficient Infection of Primary T Lymphocytes and Macrophages by R5 Human Immunodeficiency Virus Type 1 Isolates. Journal of Virology, 2003, 77, 2550-2558.	3.4	61
46	HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9475-9480.	7.1	61
47	Quinoline-based compounds as modulators of HIV transcription through NF-Î²B and Sp1 inhibition. Antiviral Research, 2010, 87, 338-344.	4.1	59
48	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	58
49	Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-Î²B pathway. Antiviral Research, 2005, 66, 137-145.	4.1	57
50	Measuring the Firing Rate of High-Resistance Neurons with Cell-Attached Recording. Journal of Neuroscience, 2012, 32, 3118-3130.	3.6	57
51	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
52	Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Research, 2010, 38, 3287-3307.	14.5	55
53	A Founder Effect Led Early SARS-CoV-2 Transmission in Spain. Journal of Virology, 2021, 95, .	3.4	55
54	SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochemical Pharmacology, 2009, 77, 965-978.	4.4	54

#	Article	IF	Citations
55	Environmentally Friendly Procedure Based on Supercritical Fluid Chromatography and Tandem Mass Spectrometry Molecular Networking for the Discovery of Potent Antiviral Compounds from Euphorbia semiperfoliata. Journal of Natural Products, 2017, 80, 2620-2629.	3.0	51
56	Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochemical Pharmacology, 2016, 106, 30-45.	4.4	50
57	Induction of an endothelial cell growth factor by human cytomegalovirus infection of fibroblasts. Journal of General Virology, 1991, 72, 2765-2770.	2.9	50
58	Anti-HIV activity of stilbene-related heterocyclic compounds. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4075-4079.	2.2	47
59	The Presence of HIV-1 Tat Protein Second Exon Delays Fas Protein-mediated Apoptosis in CD4+ T Lymphocytes. Journal of Biological Chemistry, 2013, 288, 7626-7644.	3.4	47
60	Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina. Journal of Natural Products, 2015, 78, 1045-1055.	3.0	47
61	CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. Cytokine, 2011, 53, 184-190.	3.2	44
62	Estimating functional connectivity in an electrically coupled interneuron network. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4798-E4807.	7.1	44
63	The Carboxyl-terminal Domain of Connexin43 Is a Negative Modulator of Neuronal Differentiation. Journal of Biological Chemistry, 2010, 285, 11836-11845.	3.4	43
64	MC159L protein from the poxvirus molluscum contagiosum virus inhibits NF-ÎºB activation and apoptosis induced by PKR. Journal of General Virology, 2001, 82, 3027-3034.	2.9	43
65	Prostratin Induces HIV Activation and Downregulates HIV Receptors in Peripheral Blood Lymphocytes. Antiviral Therapy, 2004, 9, 545-554.	1.0	43
66	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Reviews, 2010, 12, 135-48.	1.0	42
67	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
68	The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Scientific Reports, 2017, 7, 2385.	3.3	38
69	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Journal of Virology, 2011, 85, 5804-5813.	3.4	37
70	A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. Journal of Antimicrobial Chemotherapy, 2010, 65, 2493-2501.	3.0	35
71	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Reports, 2022, 38, 110235.	6.4	35
72	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. AIDS Reviews, 2012, 14, 208-17.	1.0	35

#	Article	IF	Citations
73	Screening of selected plant extracts for in vitro inhibitory activity on Human Immunodeficiency Virus. Phytotherapy Research, 2002, 16, 550-554.	5.8	34
74	Basal shuttle of NF-Î¹B/IÎ¹BÎ± in resting T lymphocytes regulates HIV-1 LTR dependent expression. Retrovirology, 2007, 4, 56.	2.0	34
75	Involvement of the Rac1-IRSp53-Wave2-Arp2/3 Signaling Pathway in HIV-1 Gag Particle Release in CD4 T Cells. Journal of Virology, 2015, 89, 8162-8181.	3.4	34
76	Analysis of Non-AIDS-Defining Events in HIV Controllers. Clinical Infectious Diseases, 2016, 62, 1304-1309.	5.8	34
77	Optimal use of maraviroc in clinical practice. Aids, 2008, 22, 2231-2240.	2.2	33
78	Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF-kB and Sp1 dependent transcription. European Journal of Medicinal Chemistry, 2012, 52, 295-303.	5.5	33
79	Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics, 2008, 8, 852-873.	2.2	31
80	Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. Journal of Virology, 2016, 90, 5231-5245.	3.4	31
81	Negatively Charged Glyconanoparticles Modulate and Stabilize the Secondary Structures of a gp120 V3 Loop Peptide: Toward Fully Synthetic HIV Vaccine Candidates. Bioconjugate Chemistry, 2015, 26, 755-765.	3.6	30
82	Protein Kinase CÎ¸ Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+ T Lymphocytes*. Journal of Biological Chemistry, 2011, 286, 27363-27377.	3.4	29
83	Transcriptome Sequencing of Peripheral Blood Mononuclear Cells from Elite Controller-Long Term Non Progressors. Scientific Reports, 2019, 9, 14265.	3.3	29
84	Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma. Journal of Clinical Microbiology, 2002, 40, 1518-1521.	3.9	28
85	Structureâ€Based Design of an RNAâ€Binding pâ€Terphenylene Scaffold that Inhibits HIVâ€1 Rev Protein Function. Angewandte Chemie - International Edition, 2013, 52, 13405-13409.	13.8	28
86	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clinical Infectious Diseases, 2017, 64, ciw833.	5.8	28
87	LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Virus Research, 1998, 57, 11-20.	2.2	27
88	Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication. Retrovirology, 2015, 12, 78.	2.0	27
89	A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology, 2015, 12, 50.	2.0	27
90	CCR5 structural plasticity shapes HIV-1 phenotypic properties. PLoS Pathogens, 2018, 14, e1007432.	4.7	27

#	Article	IF	Citations
91	Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 354-356.	6.7	26
92	Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. Journal of Virology, 2019, 93, .	3.4	26
93	Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. Frontiers in Immunology, 2021, 12, 665329.	4.8	26
94	Screening of South American Plants against Human Immunodeficiency Virus: Preliminary Fractionation of Aqueous Extract from Baccharis trinervis.. Biological and Pharmaceutical Bulletin, 2002, 25, 1147-1150.	1.4	25
95	Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis and Rheumatism, 2006, 54, 1473-1481.	6.7	25
96	Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits IÎºBÎ± and enhances HIV-1 replication in human T lymphocytes. Retrovirology, 2008, 5, 109.	2.0	25
97	SDF-1/CXCL12 Production by Mature Dendritic Cells Inhibits the Propagation of X4-Tropic HIV-1 Isolates at the Dendritic Cell-T-Cell Infectious Synapse. Journal of Virology, 2010, 84, 4341-4351.	3.4	25
98	Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen. Biochemical Pharmacology, 2016, 107, 14-28.	4.4	25
99	Axonal Computations. Frontiers in Cellular Neuroscience, 2019, 13, 413.	3.7	25
100	Expression of IÎºBÎ± in the nucleus of human peripheral blood T lymphocytes. Oncogene, 1999, 18, 1581-1588.	5.9	24
101	PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients. Journal of Clinical Investigation, 2020, 130, 2872-2887.	8.2	24
102	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	2.5	24
103	Antagonistic modulation of human cytomegalovirus replication by transforming growth factor beta and basic fibroblastic growth factor. Journal of General Virology, 1993, 74, 269-274.	2.9	23
104	Ellagitannins from Tuberaria lignosa as entry inhibitors of HIV. Phytomedicine, 2010, 17, 69-74.	5.3	23
105	Hydroxytyrosol. Aids, 2016, 30, 2767-2776.	2.2	23
106	Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU. Frontiers in Immunology, 2021, 12, 742631.	4.8	23
107	Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription. Biochemical Pharmacology, 2015, 94, 241-256.	4.4	22
108	The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS Pathogens, 2019, 15, e1007958.	4.7	22

#	Article	IF	Citations
109	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. Scientific Reports, 2019, 9, 5606.	3.3	22
110	Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antiviral Therapy, 2004, 9, 545-54.	1.0	22
111	c/EBPÎ² Is a Major Regulatory Element Driving Transcriptional Activation of the CXCL12 Promoter. Journal of Molecular Biology, 2010, 396, 463-472.	4.2	21
112	Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells. PLoS ONE, 2017, 12, e0185677.	2.5	21
113	Guatemalan plants extracts as virucides against HIV-1 infection. Phytomedicine, 2008, 15, 520-524.	5.3	20
114	Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression. Current HIV Research, 2009, 7, 384-389.	0.5	20
115	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS ONE, 2017, 12, e0186602.	2.5	20
116	An in Vivo Functional Immune System Lacking Polyclonal T-Cell Surface Expression of the CD3/Ti(WT31) Complex. Scandinavian Journal of Immunology, 1987, 26, 699-707.	2.7	19
117	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. BMC Medicine, 2018, 16, 30.	5.5	19
118	A small-molecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference. Biochemical Pharmacology, 2018, 156, 68-77.	4.4	19
119	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. PLoS Pathogens, 2022, 18, e1010171.	4.7	18
120	Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. Virus Genes, 2007, 34, 111-116.	1.6	17
121	Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. Aids, 2016, 30, 1015-1025.	2.2	17
122	Ethanolic extract of Artemisia campestris subsp. glutinosa (Besser) Batt. inhibits HIVâ€“1 replication in vitro through the activity of terpenes and flavonoids on viral entry and NFâ€“ÎºB pathway. Journal of Ethnopharmacology, 2020, 263, 113163.	4.1	17
123	Natural Human Antibodies Retrieved by Phage Display Libraries from Healthy Donors: Polyreactivity and Recognition of Human Immunodeficiency Virus Type 1 gp120 Epitopes. Scandinavian Journal of Immunology, 1999, 50, 270-279.	2.7	16
124	Immune Activation Promotes Evolutionary Conservation of T-Cell Epitopes in HIV-1. PLoS Biology, 2013, 11, e1001523.	5.6	16
125	Electrical Synapses Enhance and Accelerate Interneuron Recruitment in Response to Coincident and Sequential Excitation. Frontiers in Cellular Neuroscience, 2018, 12, 156.	3.7	15
126	Anti-HIV activity of some synthetic lignanolides and intermediates. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4483-4486.	2.2	14

#	Article	IF	Citations
127	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Biochemical Pharmacology, 2018, 156, 248-264.	4.4	14
128	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. Journal of Microbiology, Immunology and Infection, 2019, 52, 667-671.	3.1	14
129	Dual role of host cell factors in HIV-1 replication: restriction and enhancement of the viral cycle. AIDS Reviews, 2010, 12, 103-12.	1.0	14
130	A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence. Carcinogenesis, 2009, 30, 440-448.	2.8	13
131	MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter. Nucleic Acids Research, 2017, 45, 9960-9975.	14.5	13
132	Dasatinib protects humanized mice from acute HIV-1 infection. Biochemical Pharmacology, 2020, 174, 113625.	4.4	13
133	Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Journal of Clinical Medicine, 2021, 10, 42.	2.4	13
134	Broadly Neutralizing Antibodies and their Significance for HIV-1 Vaccines. Current HIV Research, 2010, 8, 602-612.	0.5	12
135	Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication. Retrovirology, 2013, 10, 124.	2.0	12
136	Determination of HIV tropism and its use in the clinical practice. Expert Review of Anti-Infective Therapy, 2013, 11, 1291-1302.	4.4	12
137	Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. Expert Opinion on Drug Safety, 2017, 16, 547-559.	2.4	12
138	Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development (Cambridge), 2022, 149, .	2.5	12
139	Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. Antiviral Research, 2010, 88, 152-159.	4.1	11
140	Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection. Journal of Clinical Medicine, 2020, 9, 2452.	2.4	11
141	CCR5 genotype and HIV-1 infection in perinatally-exposed infants. Journal of Infection, 1999, 38, 9-11.	3.3	10
142	A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV Medicine, 2008, 9, 160-171.	2.2	10
143	Generation and Characterization of a Defective HIV-1 Virus as an Immunogen for a Therapeutic Vaccine. PLoS ONE, 2012, 7, e48848.	2.5	10
144	Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing. PLoS ONE, 2015, 10, e0139812.	2.5	10

#	Article	IF	Citations
145	Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients. PLoS ONE, 2019, 14, e0220459.	2.5	10
146	4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat. Biochemical Pharmacology, 2020, 177, 113937.	4.4	10
147	Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis. PLoS Pathogens, 2021, 17, e1009526.	4.7	10
148	Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression. PLoS ONE, 2012, 7, e50204.	2.5	10
149	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	3.4	10
150	HIV-1 latency and eradication of long-term viral reservoirs. Discovery Medicine, 2010, 9, 185-91.	0.5	10
151	PKCÎ¸ and HIV-1 Transcriptional Regulator Tat Co-exist at the LTR Promoter in CD4+ T Cells. Frontiers in Immunology, 2016, 7, 69.	4.8	9
152	Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochemical Pharmacology, 2020, 182, 114203.	4.4	9
153	Nucleic acid recognition and antiviral activity of 1,4-substituted terphenyl compounds mimicking all faces of the HIV-1 Rev protein positively-charged Î±-helix. Scientific Reports, 2020, 10, 7190.	3.3	9
154	Use of RT-Defective HIV Virions: New Tool to Evaluate Specific Response in Chronic Asymptomatic HIV-Infected Individuals. PLoS ONE, 2013, 8, e58927.	2.5	9
155	Hot Immunological Topics in HIV Infection. Journal of AIDS & Clinical Research, 2011, 02, .	0.5	9
156	In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4. Aids, 1998, 12, 859-863.	2.2	8
157	Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1365-1382.	3.3	8
158	Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine. Vaccines, 2021, 9, 694.	4.4	8
159	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochemical Pharmacology, 2021, 192, 114666.	4.4	8
160	INDOMETHACIN IN THE RELIEF OF AIDS SYMPTOMS. Lancet, The, 1986, 328, 570.	13.7	7
161	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68.	2.0	7
162	Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-Î²B Pathways. Molecules, 2017, 22, 321.	3.8	7

#	Article	IF	Citations
163	An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies. PLoS ONE, 2016, 11, e0166902.	2.5	7
164	Reverse transcriptase-like activity in Trypanosoma cruzi. Acta Tropica, 1997, 63, 117-126.	2.0	6
165	Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins. Journal of Virological Methods, 2016, 236, 184-195.	2.1	6
166	5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract. Antiviral Research, 2017, 142, 16-20.	4.1	6
167	Different Expression of Interferon-Stimulated Genes in Response to HIV-1 Infection in Dendritic Cells Based on Their Maturation State. Journal of Virology, 2017, 91, .	3.4	6
168	Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets. Frontiers in Pharmacology, 2018, 9, 358.	3.5	6
169	In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. Journal of Medical Virology, 2009, 81, 211-216.	5.0	5
170	Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Current HIV/AIDS Reports, 2019, 16, 414-422.	3.1	5
171	Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19. Journal of Clinical Medicine, 2022, 11, 2803.	2.4	5
172	Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study. EClinicalMedicine, 2022, 51, 101542.	7.1	5
173	Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Pharmacogenomics, 2014, 15, 569-572.	1.3	4
174	Potential role of tyrosine kinase inhibitors during primary HIV-1 infection. Expert Review of Anti-Infective Therapy, 2017, 15, 421-423.	4.4	4
175	Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ÃŸ Mediation. Journal of Clinical Medicine, 2020, 9, 959.	2.4	4
176	Withanolide-Type Steroids from Physalis nicandroides Inhibit HIV Transcription. Journal of Natural Products, 2021, 84, 2717-2726.	3.0	4
177	Elevated Î±-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control. Frontiers in Immunology, 2022, 13, 822272.	4.8	4
178	The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans. IScience, 2022, , 104409.	4.1	4
179	Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors. Journal of Medical Virology, 2004, 73, 502-507.	5.0	3
180	SituaciÃ³n de la investigaciÃ³n sobre el VIH en EspaÃ±a. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 26-30.	0.5	3

#	Article	IF	Citations
181	Association of a single nucleotide polymorphism in the ubxn6 gene with long-term non-progression phenotype in HIV-positive individuals. Clinical Microbiology and Infection, 2020, 26, 107-114.	6.0	3
182	Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals. Vaccines, 2021, 9, 799.	4.4	3
183	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. EClinicalMedicine, 2022, 50, 101529.	7.1	3
184	CD11b-bearing mononuclear leucocytes and IgA levels in the staging of human immunodeficiency virus infection. Experientia, 1992, 48, 402-404.	1.2	2
185	Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients. Virology, 2017, 500, 247-258.	2.4	2
186	Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc. Journal of Virology, 2018, 92, .	3.4	2
187	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. Frontiers in Immunology, 2021, 12, 730691.	4.8	2
188	Avances en la inmunopatologÃa de la infecciÃ³n por el VIH. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 486-496.	0.5	2
189	Extensive GJD2 Expression in the Song Motor Pathway Reveals the Extent of Electrical Synapses in the Songbird Brain. Biology, 2021, 10, 1099.	2.8	2
190	Where does free infective HIV-1 rebound come from?. Aids, 2001, 15, 657.	2.2	2
191	Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Blood, 2019, 134, 191-191.	1.4	2
192	Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection. Journal of Clinical Medicine, 2022, 11, 2137.	2.4	2
193	P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group. Retrovirology, 2009, 6, .	2.0	1
194	Molecular mechanisms involved in HIV latency and implications for HIV treatment and eradication. Retrovirology, 2010, 7, .	2.0	1
195	Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection. Frontiers in Cell and Developmental Biology, 2022, 10, .	3.7	1
196	Anti-HIV Activity of Some Synthetic Lignanolides and Intermediates.. ChemInform, 2004, 35, no.	0.0	0
197	SituaciÃ³n actual en el desarrollo de una vacuna preventiva frente al VIH. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23, 5-14.	0.5	0
198	Modifications in host cell structure and functions mediated by Tat intracellular expression are greatly dependent on the second exon. Retrovirology, 2009, 6, .	2.0	0

#	Article	IF	Citations
199	Allosteric regulation by non peptidic, low molecular weight compounds of CCR5 coupling to g-proteins and interaction with Gp120 - consequences on inhibition of R5 HIV-1 infection. Retrovirology, 2010, 7, .	2.0	0
200	InnenrÃ¼cktitelbild: Structure-Based Design of an RNA-Bindingp-Terphenylene Scaffold that Inhibits HIV-1 Rev Protein Function (Angew. Chem. 50/2013). Angewandte Chemie, 2013, 125, 13719-13719.	2.0	0
201	Antiviral Activity of 5-Hydroxytyrosol, a Microbicidal Candidate against HIV-1 Transmission. AIDS Research and Human Retroviruses, 2014, 30, A240-A240.	1.1	0
202	Candidate Microbicide 5-hydroxytyrosol (5-HT) Inhibits Productive R5 HIV-1 Infection of Human Cervical Tissue Explants (CTE). AIDS Research and Human Retroviruses, 2014, 30, A264-A264.	1.1	0
203	Combinations of Entry and Reverse Transcriptase Inhibitors as Candidate Microbicides. AIDS Research and Human Retroviruses, 2014, 30, A213-A213.	1.1	0
204	Mucosal Tissue Explants as Surrogates for In Vivo Efficacy of Microbicides. AIDS Research and Human Retroviruses, 2014, 30, A60-A60.	1.1	0
205	Preclinical Evaluation of Multi-targeting Antiretroviral Drug Based-combinations as Candidate Microbicides. AIDS Research and Human Retroviruses, 2014, 30, A262-A262.	1.1	0
206	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. Journal of Virus Eradication, 2017, 3, 236-241.	0.5	0
207	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. Journal of Virus Eradication, 2017, 3, 236-241.	0.5	0
208	Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients. Frontiers in Virology, 2022, 2, .	1.4	0
209	Omic Technologies in HIV: Searching Transcriptional Signatures Involved in Long-Term Non-Progressor and HIV Controller Phenotypes. Frontiers in Immunology, 0, 13, .	4.8	0